Novartis expects higher sales and profitability this year, lifted by its broad range of drugs, and minimal disruption to its supply chain from the coronavirus outbreak in China.

Novartis has warned its profit may decline this year as it ramps up marketing spend on new heart failure drug Entresto following a disappointing start for the medicine.

Novartis employees in Shanghai have a new $1 billion home.